Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Drug Alcohol Depend ; 217: 108293, 2020 12 01.
Article in English | MEDLINE | ID: mdl-32980787

ABSTRACT

AIM: To investigate associations between substance dependence and obesity. METHODS: Obesity (body mass index ≥ 30 kg/m2) status and the status of dependence on heroin, stimulant, marijuana, nicotine and alcohol (past-month status for nicotine and past-year status for all others) were identified from the U.S. National Survey on Drug Use and Health (NSDUH, 2015-2017) datasets. SAS Surveylogistic regression was used to estimate adjusted odds ratio (AOR) for the association between each substance dependence and obesity, adjusting for potentially confounding effects of sociodemographic factors and health condition. RESULTS: It was estimated that 10.6 % of noninstitutional U.S. residents aged 12 years or older were nicotine-dependent, 3.0 % alcohol-dependent, 1.0 % marijuana-dependent, 0.6 % stimulant-dependent, and 0.2 % heroin-dependent. Heroin-dependent individuals had 59 % lower odds of obesity relative to their non-dependent counterparts (AOR = 0.41; 95 % CI: 0.28-0.60; p < 0.0001). Lower odds of obesity were also noted for marijuana-dependent (AOR = 0.64; 95 % CI: 0.56-0.73; p < 0.0001), nicotine-dependent (AOR = 0.68; 95 % CI: 0.64-0.72; p < 0.0001) and alcohol-dependent (AOR = 0.77, 95 % CI: 0.69-0.84; p < 0.0001) individuals, but not statistically significant for stimulant-dependent individuals (AOR = 0.84; 95 % CI: 0.68-1.02; p = 0.0825). CONCLUSIONS: Heroin, marijuana, nicotine and alcohol dependence were associated with lower odds of obesity than their non-dependence counterparts. Main findings based on 2015-2017 NSDUH are consistent with findings from our prior report based on clinical trials data from National Institute on Drug Abuse Clinical Trials Network, and other epidemiological evidence in the literature. These findings can alert substance abuse treatment professionals to monitor weight change, especially among weight-concerned substance abusers.


Subject(s)
Drug Users , Health Surveys/methods , Obesity/epidemiology , Substance-Related Disorders/epidemiology , Adolescent , Adult , Aged , Alcoholism/diagnosis , Alcoholism/epidemiology , Amphetamine-Related Disorders/diagnosis , Amphetamine-Related Disorders/epidemiology , Child , Cross-Sectional Studies , Female , Heroin Dependence/diagnosis , Heroin Dependence/epidemiology , Humans , Male , Marijuana Abuse/diagnosis , Marijuana Abuse/epidemiology , Middle Aged , National Institute on Drug Abuse (U.S.)/trends , Obesity/diagnosis , Prevalence , Substance-Related Disorders/diagnosis , Tobacco Use Disorder/diagnosis , Tobacco Use Disorder/epidemiology , United States/epidemiology
2.
Drug Alcohol Depend ; 206: 107733, 2020 01 01.
Article in English | MEDLINE | ID: mdl-31790978

ABSTRACT

BACKGROUND: The National Institute on Drug Abuse (NIDA) recently released a Request for Information (RFI) soliciting comments on nonhuman animal models of substance use disorders (SUD). METHODS: A literature review was performed to address the four topics outlined in the RFI and one topic inspired by the RFI: (1) animal models that best recapitulate SUD, (2) animal models that best balance the trade-offs between resources and ecological validity, (3) animal models whose translational value are frequently misrepresented or overrepresented by the scientific community, (4) aspects of SUD that are not currently being modeled in animals, and (5) animal models that are optimal for examining the basic mechanisms by which drugs produce their abuse-related effects. RESULTS: Models that employ response-contingent drug administration, use complex schedules of reinforcement, measure behaviors that mimic the distinguishing features of SUD, and use animals that are phylogenetically similar to humans have the greatest translational value. Models that produce stable and reproducible baselines of behavior, lessen the number of uncontrolled variables, and minimize the influence of extraneous factors are best at examining basic mechanisms contributing to drug reward and reinforcement. CONCLUSIONS: Nonhuman animal models of SUD have undergone significant refinements to increase their utility for basic science and translational value for SUD. The existing literature describes numerous examples of how these models may best be utilized to answer mechanistic questions of drug reward and identify potential therapeutic interventions for SUD. Progress in the field could be accelerated by further collaborations between researchers using animals versus humans.


Subject(s)
Models, Animal , Reinforcement, Psychology , Substance-Related Disorders/psychology , Substance-Related Disorders/therapy , Translational Research, Biomedical/trends , Animals , Humans , National Institute on Drug Abuse (U.S.)/trends , Reward , Species Specificity , Substance-Related Disorders/genetics , Translational Research, Biomedical/methods , United States
3.
Drug Alcohol Depend ; 190: 255-262, 2018 09 01.
Article in English | MEDLINE | ID: mdl-30077926

ABSTRACT

AIMS: To estimate obesity prevalence among drug-dependent individuals and to compare prevalence across different types of drug dependence. METHODS: 1596 opioid- and/or stimulant-dependent participants were extracted from six clinical trials within the National Drug Abuse Treatment Clinical Trials Network of the National Institute on Drug Abuse (NIDA CTN) to estimate obesity prevalence among drug-dependent users. Age-, sex-, and race-matched National Health and Nutrition Examination Survey (NHANES) samples were used as a general population reference. Standardized prevalence ratios (SPRs) were calculated to compare the CTN sample to NHANES as well as to compare within the CTN sample. Logistic regression estimated associations between the type of drug dependence and obesity. RESULTS: The standardized obesity prevalence among the drug-dependent CTN trial participants was 67% of expected for age-, sex- and race-matched NIHANES participants (SPR = 0.67, 95% CI: 0.60-0.74). Obesity was least prevalent among opioid-dependent-only participants (SPR = 0.36, 95% CI: 0.27-0.46 compared to the NHANES, and SPR = 0.33, 95% CI: 0.23-0.46 compared to the stimulant-dependent-only participants). Compared to stimulant-dependent-only users (p < 0.0001), the odds of obesity were 67% lower among opioid-dependent-only users (adjusted odds ratio [AOR] = 0.33, 95% CI: 0.23-0.46) and 33% lower among opioid and stimulant-co-dependent users (AOR = 0.67, 95%CI: 0.49-0.90) after controlling for age, sex, race, education and employment pattern. CONCLUSIONS: The prevalence of obesity among drug-dependent clinical trial participants was lower than the general population, and lowest among opioid-dependent-only users, suggesting an inverse relationship between obesity prevalence and drug dependence, most notable among opioid-dependent-only users.


Subject(s)
Central Nervous System Stimulants , Clinical Trials as Topic , Nutrition Surveys/trends , Obesity/epidemiology , Opioid-Related Disorders/epidemiology , Adult , Analgesics, Opioid/adverse effects , Central Nervous System Stimulants/adverse effects , Clinical Trials as Topic/methods , Female , Humans , Male , Middle Aged , National Institute on Drug Abuse (U.S.)/trends , Nutrition Surveys/methods , Obesity/diagnosis , Obesity/therapy , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/therapy , Prevalence , Treatment Outcome , United States/epidemiology
4.
Nicotine Tob Res ; 20(12): 1457-1466, 2018 11 15.
Article in English | MEDLINE | ID: mdl-29059423

ABSTRACT

Introduction: The US cigar market is diverse, yet until recently most research studies and tobacco surveillance systems have not reported behavioral and related outcomes by cigar type. Methods: The 2013-2014 Population Assessment of Tobacco and Health Study collected data separately for filtered cigars (FCs), cigarillos, and traditional cigars, which were further distinguished as premium or nonpremium. Descriptive statistics for adult established current smokers of each cigar type and cigarettes were calculated for demographic characteristics, tobacco use patterns, purchasing behaviors and reasons for use. Adjusted prevalence ratios (APRs) using a marginal predictions approach with logistic regression assessed correlates of dual cigar and cigarette smoking. Results: Age, sex, race/ethnicity, education level, and poverty status of smokers varied according to cigar type. Daily cigar smoking prevalence and number of cigars smoked per day were higher for FCs (37.3%; median: 1.6 cigars/day, respectively), than all other cigar types (6.7%-25.3%, all p < .01; 0.1-0.4 cigars/day, all p < .01, respectively); daily smoking and cigars per day were similar for nonpremium cigars and cigarillos (p = .11; p = .33, respectively). Cigarette smoking was twice as common among smokers of nonpremium cigars, cigarillos, and FCs (58.0%-66.0%) than among premium cigars (29.9%). Among current cigar smokers, FC smokers (APR = 1.23, 95% confidence interval [CI] = 1.09-1.39), other tobacco product users (APR = 1.27, 95% CI = 1.15-1.41), and those with a GED/high school diploma or less (APR = 1.20, 95% CI = 1.09-1.33) were more likely to also smoke cigarettes. Conclusion: User characteristics, cigar smoking patterns, and dual smoking with cigarettes varied by cigar type highlighting the importance of adequately describing the cigar type studied and, where appropriate, differentiating results by cigar type. Implications: Despite the diversity of the cigar market place, historically many research studies and tobacco surveillance systems have treated cigars as a single product type. This study describes similarities and differences in the user characteristics, tobacco use patterns, and purchasing behaviors of premium, nonpremium, cigarillo, and filtered cigar smokers. To enhance tobacco regulatory science, sufficient descriptions of the cigar type(s) studied and, where appropriate, differentiation of the particular cigar type(s) studied should be undertaken to improve the interpretation of study findings, understanding of cigar use patterns and related behaviors and future approaches to reducing cigar-attributable morbidity and mortality.


Subject(s)
Cigar Smoking/economics , Cigar Smoking/epidemiology , Consumer Behavior/economics , Population Surveillance , Tobacco Products/economics , Adolescent , Adult , Cigar Smoking/psychology , Cohort Studies , Female , Humans , Longitudinal Studies , Male , Middle Aged , National Institute on Drug Abuse (U.S.)/economics , National Institute on Drug Abuse (U.S.)/trends , Population Surveillance/methods , Smokers/psychology , Tobacco Products/classification , United States/epidemiology , United States Food and Drug Administration/economics , United States Food and Drug Administration/trends , Young Adult
5.
J Neuroimmune Pharmacol ; 11(3): 379-82, 2016 09.
Article in English | MEDLINE | ID: mdl-27484319

ABSTRACT

This special issue contains 20 papers including 3 Perspectives, 1 Brief Report, 6 Invited Reviews, and 10 Original Articles, which highlight the work by presenters at the second meeting of the biennial Conference Series to Promote Global Health held on April 22-24, 2015 in Hangzhou, Zhejiang, China. These papers focused on the prevalent substance misuse of amphetamine-type-stimulants and opioids, and the increasing prevalence of HIV-infection in Asian countries. The Conference Series is sponsored by the National Institute on Drug Abuse of the U.S. National Institutes of Health, with the goal of exchanging knowledge and ideas related to, and promoting international collaborative work on, the prevention and treatment of substance use disorders and HIV-infection, in order to promote health in Asian and Pacific Islanders and other populations.


Subject(s)
Congresses as Topic/trends , Global Health/trends , HIV Infections/epidemiology , National Institute on Drug Abuse (U.S.)/trends , Substance-Related Disorders/epidemiology , Asia/epidemiology , China/epidemiology , HIV Infections/prevention & control , HIV Infections/therapy , Humans , Substance-Related Disorders/prevention & control , Substance-Related Disorders/therapy , Treatment Outcome , United States/epidemiology
6.
J Stud Alcohol Drugs ; 77(1): 160-9, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26751366

ABSTRACT

OBJECTIVE: The National Institute on Drug Abuse (NIDA) recommends a comprehensive treatment program for individuals with substance use disorder (SUD) in order to treat needs they often have in addition to their SUD. Specifically, NIDA suggests providing services related to the following issues: medical care, mental health care, HIV/AIDS, child care, educational, vocational, family counseling, housing, transportation, financial, and legal. By providing a comprehensive model that combines core and wraparound services, treatment centers can deliver a higher quality of treatment. In this article, we assessed the relationship between client characteristics and the availability of wraparound services in SUD treatment centers. METHOD: We combined two nationally representative samples of treatment centers and used a negative binomial regression and a series of logistic regressions to analyze the relationship between client characteristics and wraparound services. RESULTS: On average, centers offered fewer than half of the wraparound services endorsed by NIDA. Our results indicated that client characteristics were significantly related to the provision of wraparound services. Most notably, the proportion of adolescent clients was positively related to educational services, the proportion of female clients was positively related to child care, but the proportion of clients referred from the criminal justice system was negatively associated with the provision of multiple wraparound services. CONCLUSIONS: Our findings have important implications for SUD clients and suggest that, although centers are somewhat responsive to their clients' ancillary needs, most centers do not offer the majority of wraparound services.


Subject(s)
National Institute on Drug Abuse (U.S.) , Substance Abuse Treatment Centers/methods , Substance-Related Disorders/epidemiology , Substance-Related Disorders/therapy , United States Substance Abuse and Mental Health Services Administration , Adolescent , Adult , Cross-Sectional Studies , Female , Humans , Male , National Institute on Drug Abuse (U.S.)/trends , Substance Abuse Treatment Centers/statistics & numerical data , Substance Abuse Treatment Centers/trends , Substance-Related Disorders/diagnosis , United States/epidemiology , United States Substance Abuse and Mental Health Services Administration/trends , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...